+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cytomegalovirus Tests Market - Global Forecast to 2030- Product Image
Cytomegalovirus Tests Market - Global Forecast to 2030- Product Image
Sale

Cytomegalovirus Tests Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968363
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cytomegalovirus Tests Market grew from USD 680.78 million in 2024 to USD 731.24 million in 2025. It is expected to continue growing at a CAGR of 7.07%, reaching USD 1.02 billion by 2030.

Cytomegalovirus (CMV) remains a critical concern in clinical diagnostics due to its high prevalence and potential to cause severe disease in immunocompromised patients, neonates, and transplant recipients. Advances in antigenemia assays, molecular tests, and serology assays have expanded diagnostic capabilities, enabling earlier detection and more precise monitoring of viral activity. This executive summary outlines the current state of CMV testing, highlighting key technological innovations, shifting regulatory and trade dynamics, and strategic segmentation that drive market participation. By examining the evolving testing landscape, tariff impacts, regional and corporate trends, and actionable recommendations, stakeholders can navigate decision-making with clarity and confidence. Transitioning from foundational context to targeted insights, this overview equips industry leaders with a comprehensive understanding of opportunities and challenges in the CMV diagnostics arena.

Transformative Shifts in Cytomegalovirus Testing Landscape

The CMV testing landscape is undergoing transformative shifts as digital health integration, automation, and novel biotechnologies converge. Polymerase chain reaction methods are being enhanced by real-time quantitative assays, enabling rapid viral load quantification, while next-generation sequencing platforms offer comprehensive strain analysis to inform personalized therapy. Immunoassays have evolved from traditional enzyme-linked tests to fluorescent and chemiluminescent formats, improving sensitivity and turnaround time. Concurrently, regulatory bodies are streamlining approval pathways for in vitro diagnostics, accelerating market entry for advanced assays. The rise in telemedicine and electronic health record interoperability further positions CMV testing for decentralized delivery, allowing remote monitoring of at-risk populations. These converging dynamics empower clinical laboratories and point-of-care settings to adopt sophisticated workflows that enhance patient outcomes and operational efficiency.

Cumulative Impact of United States Tariffs 2025 on CMV Testing

United States tariffs implemented in early 2025 have reshaped supply chains for CMV testing reagents, instrumentation, and consumables. Levies on imported molecular platforms and sequencing reagents have driven manufacturers to explore alternative sourcing and local partnerships. As a result, some global suppliers are diversifying their manufacturing footprint to mitigate cost pressures and avoid elongated lead times. Diagnostic laboratories and blood banks are negotiating volume agreements and embracing reagent rental models to preserve budget predictability. Despite short-term pricing challenges, these adjustments are fostering innovation in reagent formulation and streamlined workflows. In response to trade uncertainty, industry stakeholders are strengthening domestic capabilities, reinforcing resilience against future policy fluctuations.

Key Segmentation Insights for Strategic Positioning

Market segmentation reveals strategic entry points across multiple dimensions. Based on test type, direct and indirect antigenemia assays serve rapid screening needs, while DNA hybridization and polymerase chain reaction methods enable precise viral load quantification. Serology assays, including enzyme-linked immunosorbent, fluorescence, and radioimmunoassays, support immune status assessment. End-user segmentation spans national and private blood banks, hospital-based and independent diagnostic laboratories, private and public hospitals, and research institutions from academic centers to biotechnology firms. Application segmentation underscores critical workflows in neonatal congenital and swab-based testing, prenatal amniocentesis and serological screening, and transplantation testing focused on donor DNA analysis and recipient serology. PCR and sequencing technologies deliver targeted insights through quantitative and real-time PCR modalities, as well as next-generation and Sanger sequencing. Sample type considerations include plasma and whole blood, oral swab and salivary gland fluid, alongside 24-hour and random urine collections. Differentiating between acute and asymptomatic primary infections and latent versus symptomatic recurrence further refines diagnostic pathways and guides therapeutic interventions.

Key Regional Insights Shaping Market Expansion

Regional characteristics are shaping market dynamics in distinct ways. In the Americas, robust reimbursement frameworks and large public health initiatives drive adoption of high-throughput molecular assays. Europe, Middle East & Africa present heterogeneous regulatory environments, with some markets favoring point-of-care antigen tests and others investing heavily in centralized molecular labs. In Asia-Pacific, rapidly expanding healthcare infrastructure and growing awareness of congenital CMV underscore demand for both serological and PCR-based screening, especially in urban centers. Strategic partnerships with regional distributors and localized validation studies accelerate market penetration. Recognizing these variations enables stakeholders to allocate resources efficiently and tailor product portfolios to meet localized clinical and regulatory requirements.

Key Company Perspectives Driving Innovation

Leading diagnostic and life science companies are driving continuous innovation in CMV testing. Abbexa Ltd. and Creative Diagnostics are advancing novel antibody reagents, while Abbott Laboratories and Bio-Rad Laboratories focus on integrated immunoassay platforms with automated workflows. Accubiotech Co., Ltd and CTK Biotech Inc. by SSI Diagnostica have introduced rapid point-of-care antigen kits to support on-site screening. Agilent Technologies, Inc. and Thermo Fisher Scientific Inc. invest heavily in next-generation sequencing and quantitative PCR instrumentation optimized for viral diagnostics. Atlas Medical GmbH and CLONIT srl are exploring multiplexed assays for simultaneous detection of CMV and co-infections. Diasorin S.p.A. and F. Hoffmann-La Roche Ltd. drive serology assay enhancements, while Elabscience Bionovation Inc., Hangzhou Realy Tech Co., Ltd., and Jiangsu Macro & Micro-Test Med-Tech Co., Ltd. expand reagent manufacturing capacity. Intec Products, Inc., IQ Products B.V., Biogenix Inc. Pvt. Ltd., and Meridian Bioscience, Inc. by SD Biosensor collaborate on assay validation studies to ensure global compliance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize supply chain resilience by diversifying sourcing strategies and establishing regional manufacturing partnerships. Investing in emerging molecular and sequencing platforms will position organizations at the forefront of precision diagnostics, while allocating resources to point-of-care antigen and rapid serology assays addresses urgent screening needs. Strengthening collaborations with academic and biotechnology research laboratories can accelerate assay validation and foster innovation. Emphasizing digital integration-such as laboratory information management systems and telehealth connectivity-enhances data-driven decision making. Additionally, focusing on underserved segments, including neonatal and transplant testing, can uncover high-value opportunities. Proactive engagement with regulatory bodies will streamline approval pathways, and developing adaptable pricing models will mitigate the effects of trade policy volatility.

Conclusion: Navigating the Future of CMV Testing

The convergence of advanced assay technologies, evolving trade dynamics, and nuanced regional needs underscores the complexity of the CMV diagnostics landscape. Strategic segmentation across test types, end users, applications, technologies, sample types, and infection categories informs targeted product development and marketing initiatives. Companies that embrace innovation in molecular and sequencing platforms, foster resilient supply chains, and cultivate regional partnerships will gain competitive advantage. By implementing the recommendations outlined above, stakeholders can enhance patient outcomes, optimize operational efficiency, and navigate policy uncertainties with confidence. This cohesive approach ensures sustained growth and leadership in a market defined by rapid change and critical clinical impact.

Market Segmentation & Coverage

This research report categorizes the Cytomegalovirus Tests Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Antigenemia Assays
    • Direct Antigenemia Assay
    • Indirect Antigenemia Assay
  • Molecular Tests
    • DNA Hybridization Tests
    • Polymerase Chain Reaction Tests
  • Serology Tests
    • Enzyme-Linked Immunosorbent Assay
    • Fluorescence Assay
    • Radioimmunoassay
  • Blood Banks
    • National Blood Banks
    • Private Blood Centers
  • Diagnostic Laboratories
    • Hospital-Based Laboratories
    • Independent Laboratories
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Research Laboratories
    • Academic Research Laboratories
    • Biotechnology Companies
  • Neonatal Testing
    • Congenital CMV Testing
    • Swab Tests
  • Prenatal Testing
    • Amniocentesis
    • Serological Prenatal Testing
  • Transplantation Testing
    • DNA Testing for Donors
    • Serological Testing in Transplant Recipients
  • PCR Technology
    • Quantitative PCR
    • Real-Time PCR
  • Sequencing Technology
    • Next-Generation Sequencing
    • Sanger Sequencing
  • Blood Sample
    • Plasma
    • Whole Blood
  • Saliva Sample
    • Oral Swab
    • Salivary Gland Assessment
  • Urine Sample
    • 24-hour Urine Sample
    • Random Urine
  • Primary CMV Infection
    • Acute Primary Infection
    • Asymptomatic Primary Infection
  • Recurrent CMV Infection
    • Latent Recurrent Infection
    • Symptomatic Recurrence

This research report categorizes the Cytomegalovirus Tests Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Cytomegalovirus Tests Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbexa Ltd.
  • Abbott Laboratories
  • Accubiotech Co., Ltd
  • AdvaCare Pharma USA
  • Agilent Technologies, Inc.
  • Atlas Medical GmbH
  • Bio-Rad Laboratories, Inc.
  • Biogenix Inc. Pvt. Ltd.
  • CLONIT srl
  • Creative Diagnostics
  • CTK Biotech Inc. by SSI Diagnostica A/S
  • Diasorin S.p.A.
  • Elabscience Bionovation Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hangzhou Realy Tech Co., Ltd.
  • Intec Products, Inc.
  • IQ Products B.V.
  • Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
  • Meridian Bioscience, Inc. by SD Biosensor
  • Thermo Fisher Scientific Inc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cytomegalovirus Tests Market, by Test Type
8.1. Introduction
8.2. Antigenemia Assays
8.2.1. Direct Antigenemia Assay
8.2.2. Indirect Antigenemia Assay
8.3. Molecular Tests
8.3.1. DNA Hybridization Tests
8.3.2. Polymerase Chain Reaction Tests
8.4. Serology Tests
8.4.1. Enzyme-Linked Immunosorbent Assay
8.4.2. Fluorescence Assay
8.4.3. Radioimmunoassay
9. Cytomegalovirus Tests Market, by End-User
9.1. Introduction
9.2. Blood Banks
9.2.1. National Blood Banks
9.2.2. Private Blood Centers
9.3. Diagnostic Laboratories
9.3.1. Hospital-Based Laboratories
9.3.2. Independent Laboratories
9.4. Hospitals
9.4.1. Private Hospitals
9.4.2. Public Hospitals
9.5. Research Laboratories
9.5.1. Academic Research Laboratories
9.5.2. Biotechnology Companies
10. Cytomegalovirus Tests Market, by Application
10.1. Introduction
10.2. Neonatal Testing
10.2.1. Congenital CMV Testing
10.2.2. Swab Tests
10.3. Prenatal Testing
10.3.1. Amniocentesis
10.3.2. Serological Prenatal Testing
10.4. Transplantation Testing
10.4.1. DNA Testing for Donors
10.4.2. Serological Testing in Transplant Recipients
11. Cytomegalovirus Tests Market, by Technology
11.1. Introduction
11.2. PCR Technology
11.2.1. Quantitative PCR
11.2.2. Real-Time PCR
11.3. Sequencing Technology
11.3.1. Next-Generation Sequencing
11.3.2. Sanger Sequencing
12. Cytomegalovirus Tests Market, by Sample Type
12.1. Introduction
12.2. Blood Sample
12.2.1. Plasma
12.2.2. Whole Blood
12.3. Saliva Sample
12.3.1. Oral Swab
12.3.2. Salivary Gland Assessment
12.4. Urine Sample
12.4.1. 24-hour Urine Sample
12.4.2. Random Urine
13. Cytomegalovirus Tests Market, by Infection Type
13.1. Introduction
13.2. Primary CMV Infection
13.2.1. Acute Primary Infection
13.2.2. Asymptomatic Primary Infection
13.3. Recurrent CMV Infection
13.3.1. Latent Recurrent Infection
13.3.2. Symptomatic Recurrence
14. Americas Cytomegalovirus Tests Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Cytomegalovirus Tests Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Cytomegalovirus Tests Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbexa Ltd.
17.3.2. Abbott Laboratories
17.3.3. Accubiotech Co., Ltd
17.3.4. AdvaCare Pharma USA
17.3.5. Agilent Technologies, Inc.
17.3.6. Atlas Medical GmbH
17.3.7. Bio-Rad Laboratories, Inc.
17.3.8. Biogenix Inc. Pvt. Ltd.
17.3.9. CLONIT srl
17.3.10. Creative Diagnostics
17.3.11. CTK Biotech Inc. by SSI Diagnostica A/S
17.3.12. Diasorin S.p.A.
17.3.13. Elabscience Bionovation Inc.
17.3.14. F. Hoffmann-La Roche Ltd.
17.3.15. Hangzhou Realy Tech Co., Ltd.
17.3.16. Intec Products, Inc.
17.3.17. IQ Products B.V.
17.3.18. Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
17.3.19. Meridian Bioscience, Inc. by SD Biosensor
17.3.20. Thermo Fisher Scientific Inc
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. CYTOMEGALOVIRUS TESTS MARKET MULTI-CURRENCY
FIGURE 2. CYTOMEGALOVIRUS TESTS MARKET MULTI-LANGUAGE
FIGURE 3. CYTOMEGALOVIRUS TESTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. CYTOMEGALOVIRUS TESTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. CYTOMEGALOVIRUS TESTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CYTOMEGALOVIRUS TESTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIRECT ANTIGENEMIA ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INDIRECT ANTIGENEMIA ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DNA HYBRIDIZATION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY POLYMERASE CHAIN REACTION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY FLUORESCENCE ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NATIONAL BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIVATE BLOOD CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ACADEMIC RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY CONGENITAL CMV TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SWAB TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY AMNIOCENTESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DNA TESTING FOR DONORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGICAL TESTING IN TRANSPLANT RECIPIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ORAL SWAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVARY GLAND ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY 24-HOUR URINE SAMPLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RANDOM URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ACUTE PRIMARY INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ASYMPTOMATIC PRIMARY INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY LATENT RECURRENT INFECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SYMPTOMATIC RECURRENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 151. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 152. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 153. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 154. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 155. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 157. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 158. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 159. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 160. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 162. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 163. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 164. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 168. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 169. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 170. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 171. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 172. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 173. CANADA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 174. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 175. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 176. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 177. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 178. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 181. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 183. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 185. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 186. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 187. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 188. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 190. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 191. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 192. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 193. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 194. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 195. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 196. MEXICO CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES CYTOMEGALOVIRUS TESTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC CYTOMEGALOVIRUS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 268. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 269. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 270. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 271. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 272. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 274. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 275. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 276. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 277. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 279. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 280. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 281. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 283. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 284. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 285. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 286. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 287. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 288. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 289. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 290. CHINA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 291. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 292. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 293. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 294. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 295. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 296. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 297. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 298. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 300. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 302. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 303. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 304. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 305. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PCR TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 306. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEQUENCING TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 308. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD SAMPLE, 2018-2030 (USD MILLION)
TABLE 309. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SALIVA SAMPLE, 2018-2030 (USD MILLION)
TABLE 310. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY URINE SAMPLE, 2018-2030 (USD MILLION)
TABLE 311. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 312. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRIMARY CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 313. INDIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RECURRENT CMV INFECTION, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY ANTIGENEMIA ASSAYS, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY SEROLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY BLOOD BANKS, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY NEONATAL TESTING, 2018-2030 (USD MILLION)
TABLE 325. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 326. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TRANSPLANTATION TESTING, 2018-2030 (USD MILLION)
TABLE 327. INDONESIA CYTOMEGALOVIRUS TESTS MARKET SIZE, BY TECHNOLOGY, 2018-203

Companies Mentioned

  • Abbexa Ltd.
  • Abbott Laboratories
  • Accubiotech Co., Ltd
  • AdvaCare Pharma USA
  • Agilent Technologies, Inc.
  • Atlas Medical GmbH
  • Bio-Rad Laboratories, Inc.
  • Biogenix Inc. Pvt. Ltd.
  • CLONIT srl
  • Creative Diagnostics
  • CTK Biotech Inc. by SSI Diagnostica A/S
  • Diasorin S.p.A.
  • Elabscience Bionovation Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hangzhou Realy Tech Co., Ltd.
  • Intec Products, Inc.
  • IQ Products B.V.
  • Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.
  • Meridian Bioscience, Inc. by SD Biosensor
  • Thermo Fisher Scientific Inc

Methodology

Loading
LOADING...

Related Topics

Related Reports

2024-2029 Global CMV Testing Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities - Product Image

2024-2029 Global CMV Testing Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

  • Report
  • Europe, Global, Japan, ... Europe, Global, Japan, United States
From
2024-2028 Global Cytomegalovirus (CMV) Testing in 90 Countries: Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation - Product Image

2024-2028 Global Cytomegalovirus (CMV) Testing in 90 Countries: Five-Year Volume and Sales Forecasts, Supplier Sales and Shares, Competitive Analysis, Diagnostic Assays and Instrumentation

  • Report
  • Global
From
Cytomegalovirus Treatment Market - Global Forecast to 2030 - Product Image

Cytomegalovirus Treatment Market - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Cytomegalovirus (CMV) Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 - Product Image

Cytomegalovirus (CMV) Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036

  • Report
  • 52 Pages
  • Global
From
Cytomegalovirus (CMV) Treatment - Global Strategic Business Report - Product Image

Cytomegalovirus (CMV) Treatment - Global Strategic Business Report

  • Report
  • 384 Pages
  • Global
From

About the Cytomegalovirus Test Market

The Cytomegalovirus Test is a type of infectious disease test used to detect the presence of the cytomegalovirus (CMV) in a patient's body. CMV is a common virus that can cause serious health problems in people with weakened immune systems. The test is used to diagnose CMV infection, monitor the progression of the infection, and determine the effectiveness of treatment. It is also used to screen pregnant women for CMV infection, as it can cause birth defects if the mother is infected. The Cytomegalovirus Test market is composed of a variety of diagnostic companies that offer tests for CMV. These companies provide a range of products, including ELISA kits, PCR kits, and rapid tests. Some of the companies in the market include Abbott, Bio-Rad, Roche, Siemens, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.